Stephen L Seliger1, Terry Watnick1, Andrew D Althouse2, Ronald D Perrone3, Kaleab Z Abebe2, Kenneth R Hallows4, Dana C Miskulin2, Kyongtae T Bae3,5. 1. Department of Medicine, Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland. 2. Department of Medicine, Division of Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. 4. Department of Medicine, Division of Nephrology and Hypertension, University of Southern California Keck School of Medicine, Los Angeles, California. 5. Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) has been associated with metabolic disturbances characterized by downregulation of AMP-activated protein kinase (AMPK), a critical sensor of the cellular energy status. Therapeutic activation of AMPK by metformin could inhibit cyst enlargement by inhibition of both the mammalian target of rapamycin pathway and fluid secretion via the CFTR chloride channel. METHODS: We designed a phase-2, randomized, placebo-controlled, clinical trial to assess the safety, tolerability, and efficacy of metformin on total kidney volume in adults without diabetes (age 18-60 years) with ADPKD and eGFR of ≥50 ml/min per 1.73 m2. There were no eligibility criteria relating to kidney volume. In addition to demographics and clinical/family history, baseline parameters included eGFR, total kidney and liver volumes measured by MRI, and patient-reported outcomes were ascertained by the Medical Outcomes Study Short Form-36, the Gastrointestinal Safety Rating Scale, and the HALT-PKD pain questionnaire. RESULTS: We successfully randomized 97 participants recruited from two university-based clinical sites in Baltimore and Boston. The mean age of participants was 41.9 years, 72% were female, and 94% of participants were White. The majority of study participants had early stage disease, with a mean eGFR of 86.8±19.0 ml/min per 1.73 m2. Approximately half of the study participants (48%) were classified as high risk for progression (Mayo imaging classes 1C, 1D, or 1E). There was no correlation between kidney and/or liver size and health-related quality of life (HRQoL) or gastrointestinal symptom severity. CONCLUSIONS: We report successful recruitment in this ongoing, novel, clinical trial of metformin in ADPKD, with a study sample comprising patients with early stage disease and nearly a half of participants considered at high estimated risk for progression. Participants reported a low gastrointestinal symptom burden at baseline, and HRQoL similar to that of the general population, with no differences in symptoms or HRQoL related to organomegaly. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (TAME), NCT02656017.
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) has been associated with metabolic disturbances characterized by downregulation of AMP-activated protein kinase (AMPK), a critical sensor of the cellular energy status. Therapeutic activation of AMPK by metformin could inhibit cyst enlargement by inhibition of both the mammalian target of rapamycin pathway and fluid secretion via the CFTR chloride channel. METHODS: We designed a phase-2, randomized, placebo-controlled, clinical trial to assess the safety, tolerability, and efficacy of metformin on total kidney volume in adults without diabetes (age 18-60 years) with ADPKD and eGFR of ≥50 ml/min per 1.73 m2. There were no eligibility criteria relating to kidney volume. In addition to demographics and clinical/family history, baseline parameters included eGFR, total kidney and liver volumes measured by MRI, and patient-reported outcomes were ascertained by the Medical Outcomes Study Short Form-36, the Gastrointestinal Safety Rating Scale, and the HALT-PKD pain questionnaire. RESULTS: We successfully randomized 97 participants recruited from two university-based clinical sites in Baltimore and Boston. The mean age of participants was 41.9 years, 72% were female, and 94% of participants were White. The majority of study participants had early stage disease, with a mean eGFR of 86.8±19.0 ml/min per 1.73 m2. Approximately half of the study participants (48%) were classified as high risk for progression (Mayo imaging classes 1C, 1D, or 1E). There was no correlation between kidney and/or liver size and health-related quality of life (HRQoL) or gastrointestinal symptom severity. CONCLUSIONS: We report successful recruitment in this ongoing, novel, clinical trial of metformin in ADPKD, with a study sample comprising patients with early stage disease and nearly a half of participants considered at high estimated risk for progression. Participants reported a low gastrointestinal symptom burden at baseline, and HRQoL similar to that of the general population, with no differences in symptoms or HRQoL related to organomegaly. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (TAME), NCT02656017.
Authors: Kenneth R Hallows; Gary P Kobinger; James M Wilson; Lee A Witters; J Kevin Foskett Journal: Am J Physiol Cell Physiol Date: 2003-01-02 Impact factor: 4.249
Authors: Stephen L Seliger; Kaleab Z Abebe; Kenneth R Hallows; Dana C Miskulin; Ronald D Perrone; Terry Watnick; Kyongtae Tae Bae Journal: Am J Nephrol Date: 2018-05-18 Impact factor: 3.754
Authors: Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva Journal: N Engl J Med Date: 2017-11-04 Impact factor: 91.245
Authors: Fouad T Chebib; Ronald D Perrone; Arlene B Chapman; Neera K Dahl; Peter C Harris; Michal Mrug; Reem A Mustafa; Anjay Rastogi; Terry Watnick; Alan S L Yu; Vicente E Torres Journal: J Am Soc Nephrol Date: 2018-09-18 Impact factor: 10.121
Authors: Godela M Brosnahan; Wei Wang; Berenice Gitomer; Taylor Struemph; Diana George; Zhiying You; Kristen L Nowak; Jelena Klawitter; Michel B Chonchol Journal: Am J Kidney Dis Date: 2021-08-12 Impact factor: 8.860
Authors: Elise Hoover; Ronald D Perrone; Chris Rusconi; Beverly Benson; Neera K Dahl; Berenice Gitomer; Amy Manelli; Michal Mrug; Meyeon Park; Stephen L Seliger; Milind A Phadnis; Nadeesha Thewarapperuma; Terry J Watnick Journal: Kidney360 Date: 2022-05-20
Authors: Sarah R Senum; Ying Sabrina M Li; Katherine A Benson; Giancarlo Joli; Eric Olinger; Sravanthi Lavu; Charles D Madsen; Adriana V Gregory; Ruxandra Neatu; Timothy L Kline; Marie-Pierre Audrézet; Patricia Outeda; Cherie B Nau; Esther Meijer; Hamad Ali; Theodore I Steinman; Michal Mrug; Paul J Phelan; Terry J Watnick; Dorien J M Peters; Albert C M Ong; Peter J Conlon; Ronald D Perrone; Emilie Cornec-Le Gall; Marie C Hogan; Vicente E Torres; John A Sayer; Peter C Harris Journal: Am J Hum Genet Date: 2021-12-09 Impact factor: 11.043